XBiotech (XBIT) Downgraded by BidaskClub to “Buy”

BidaskClub downgraded shares of XBiotech (NASDAQ:XBIT) from a strong-buy rating to a buy rating in a report released on Thursday.

Separately, ValuEngine raised shares of XBiotech from a hold rating to a buy rating in a research report on Monday, January 7th.

XBIT traded up $0.67 on Thursday, reaching $9.76. 400 shares of the company traded hands, compared to its average volume of 169,602. XBiotech has a 52-week low of $2.13 and a 52-week high of $10.88.



In other news, major shareholder Fondation Rennes acquired 4,200 shares of XBiotech stock in a transaction dated Saturday, December 21st. The stock was acquired at an average cost of $6.24 per share, for a total transaction of $26,208.00. Following the completion of the purchase, the insider now owns 3,590,182 shares of the company’s stock, valued at $22,402,735.68. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director W Thorpe Mckenzie acquired 24,838 shares of XBiotech stock in a transaction dated Monday, December 24th. The stock was purchased at an average price of $5.88 per share, with a total value of $146,047.44. Following the completion of the purchase, the director now directly owns 3,398,600 shares of the company’s stock, valued at approximately $19,983,768. The disclosure for this purchase can be found here. Insiders bought 167,111 shares of company stock valued at $1,342,333 over the last 90 days. 37.00% of the stock is owned by corporate insiders.

Several institutional investors have recently modified their holdings of the company. Virtu Financial LLC acquired a new position in XBiotech during the 4th quarter valued at $80,000. Vanguard Group Inc raised its stake in XBiotech by 5.5% during the 3rd quarter. Vanguard Group Inc now owns 834,523 shares of the biopharmaceutical company’s stock valued at $2,654,000 after purchasing an additional 43,648 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in XBiotech by 5.5% during the 3rd quarter. Vanguard Group Inc. now owns 834,523 shares of the biopharmaceutical company’s stock valued at $2,654,000 after purchasing an additional 43,648 shares during the last quarter. Institutional investors and hedge funds own 3.12% of the company’s stock.

XBiotech Company Profile

XBiotech Inc, a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.

See Also: What are the benefits of momentum investing?

Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply